Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean‐Michel Molina, Steven L. Chuck, Andrew Cheng et al.|The Lancet Infectious Diseases|2011Cited by 172
A Randomized Phase 3 Study Comparing Once-Daily Elvitegravir With Twice-Daily Raltegravir in Treatment-Experienced Subjects With HIV-1 infectionRichard Elion, Javier Szwarcberg, José Ramón Arribas et al.|JAIDS Journal of Acquired Immune Deficiency Syndromes|2013Cited by 41
A Randomized Study of Tenofovir Disoproxil Fumarate in Treatment-experienced HIV-1 Infected AdolescentsMarinella Della Negra, Martin S. Rhee, Jeffrey Enejosa et al.|The Pediatric Infectious Disease Journal|2012Cited by 24